Tag Archives: ACS

Cortar las valvas, una medida extrema para evitar la oclusión coronaria post TAVI

Acute Coronary Syndromes After TAVR: Frequent and Not All Undergo Coronary Angiography

Acute Coronary Syndromes After TAVR: Frequent and Not All Undergo Coronary Angiography

Approximately 10% of patients who undergo transcatheter aortic valve replacement (TAVR) are readmitted for an acute coronary syndrome after a mean follow-up of 25 months. Male sex, prior coronary artery disease, and (surprisingly and hard to explain) nontransfemoral approach were independent predictors of acute coronary syndrome after TAVR, an event associated with high midterm mortality. While

Patients with Plaque Erosion: Management without Stenting

This small study presented at ESC and simultaneously published in the European Heart Journal evaluated patients undergoing acute coronary syndrome caused by plaque erosion identified by optical computed tomography (OCT). The study showed it can be managed with conservative antithrombotic therapy and without stenting.   Patients with plaque erosion can receive dual antiplatelet therapy, ticagrelor and aspirin

acceso radial sangrado

No Extra Benefit for Combined Use of Bivalirudin and Transradial Approach

The aim of this meta-analyzis was to study the relation between bivalirudin and access site in patients undergoing acute coronary syndrome (ACS). Both bivalirudin and the transradial access site are strategies aiming at reducing bleeding complication in patients with ACS undergoing invasive approaches. The interaction of both strategies and the potential benefits of their combined use

bernardo cortese

MATRIX: Transradial vs. Femoral Access in Non-ST Elevation AMI

Original Title: Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation. Presenter: Bernardo Cortese.   The MATRIX study showed that the transradial access is associated with a reduction of combined events, death, infarction, stroke and bleeding, compared to femoral access, in ACS patients. The goal of this sub-analyzis was

DANAMI 3: Deferred Stenting and Ischemic Postconditioning Have No Benefit in Primary PCI

Both ischemic postconditioning and deferred stenting showed no benefit in randomized studies conducted as part of the DANAMI 3 program. Both the DANAMI 3-DEFER and the DANAMI 3-iPOSTshowed slight improvements in ventricular function after intervention, but clinical end points saw no change. This does not mean that outcomes should be considered negative, only that the

EARLY-BAMI: Metropol Showed No Reduction in Infarct Size.

EARLY-BAMI outcomes show the endovenous administration of metropol before primary PCI does not reduce infarct size. This double blind study randomized 683 STEMI patients within 12 hours of symptom onset to endovenous metropol (two 5 mg bolus, the first in the ambulance and the second before PCI) vs. placebo. Primary end point was infarct size

New Meta-Analysis Shows Similar Mortality between Bivalirudin and Heparin

This meta-analyzis of contemporary studies comparing the safety and efficacy of bivalirudin vs. heparin showed no differences in mortality between the two drugs and, consistently with other studies, bivalirudin was associated with an increased risk of acute stent thrombosis. During ACC 2015, the MATRIX study did succeed in showing global differences between the two drugs


Immediate vs. delayed intervention in non-ST-elevation myocardial infarction

Original Title: Immediate Versus Delayed Invasive Intervention for Non-ST-Segment Elevation Myocardial Infarction Patients The RIDDLE-NSTEMI Study (Randomized study of ImmeDiate versus DeLayedinvasivE intervention in patients with Non-ST-segment Elevation Myocardial Infarction). Reference: J Am CollCardiolIntv. 2016. Online before print.   This study assessed the clinical impact of immediate invasive intervention (within 2 hours) vs. delayed intervention (within